ZBTB33 and prostate carcinoma: Interestingly, our data also showed increased binding of KAISO in AA TNBC lines (Fig. 2B), whose aberrant expression has been previously linked to a distinct biology and poor outcomes in AA patients with breast and prostate cancer (36–38).